<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13185">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01780207</url>
  </required_header>
  <id_info>
    <org_study_id>066/10</org_study_id>
    <nct_id>NCT01780207</nct_id>
  </id_info>
  <brief_title>Impact Of Closure Of Patent Foramen Ovale On Apnoea-Hypopnoea-Index, Nocturnal Hypoxemia And Systemic Vascular Function In Patients With Obstructive Sleep Apnoea</brief_title>
  <official_title>Impact Of Closure Of Patent Foramen Ovale On Apnoea-Hypopnoea-Index, Nocturnal Hypoxemia And Systemic Vascular Function In Patients With Obstructive Sleep Apnoea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <authority>Switzerland: Ethikkomission</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study in patients with obstructive sleep apnoea (OSA) and concomitant
      patent foramen ovale (PFO) is to assess the impact of percutaneous PFO closure on nocturnal
      hypoxemia and apnea/hypopnea,  pulmonary and systemic artery pressure, endothelial function
      and arterial stiffness.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>Apnea Hypopnea Index (AHI), apnea index (changes from baseline to follow-up)</measure>
    <time_frame>0, 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic vascular assessment</measure>
    <time_frame>0, 3 months</time_frame>
  </secondary_outcome>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>OSA without PFO</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OSA with PFO</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PFO closure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PFO Closure</intervention_name>
    <arm_group_label>OSA with PFO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly diagnosed moderate to severe OSA

          -  Age &gt; 17 years

          -  Written informed consent for study participation.

        Exclusion Criteria:

          -  Patients with other pulmonary disease associated with oxygen desaturation (other than
             obesity-associated pulmonary restriction)

          -  Patients with central sleep apnea syndrome

          -  Patients with other causes of pulmonary hypertension

          -  Intracardiac shunt other than via PFO

          -  Severe valvular heart disease

          -  Abnormal left ventricular (LV) systolic function (ejection fraction &lt;50%)

          -  Obesity with BMI &gt; 40

          -  Contraindication to TOE

          -  Severe pulmonary  arterial hypertension (mean pulmonary artery pressure &gt; 45 mmHg)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Stefano Rimoldi, MD</last_name>
    <phone>+41316322111</phone>
    <email>stefano.rimoldi@insel.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Rimoldi, MD</last_name>
      <phone>+41316322111</phone>
      <email>stefano.rimoldi@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Stefano Rimoldi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 29, 2013</lastchanged_date>
  <firstreceived_date>January 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Inselspital, Berne</investigator_affiliation>
    <investigator_full_name>Christian Seiler</investigator_full_name>
    <investigator_title>MD Prof</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Foramen Ovale, Patent</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
